| Type 2 Diabetes Mellitus |
1 |
1 |
| Child |
0 |
1 |
| Body Mass Index |
0 |
0.49 |
| GLP-1 Receptor Agonist |
0 |
1 |
| Adolescent Medicine |
0 |
1 |
| Food and Drug Administration (FDA) |
0 |
1 |
| Obesity |
0 |
0.3 |
| Impairment |
0 |
0.24 |
| Receptors |
0 |
0.24 |
| Health Insurance |
0 |
0.17 |
| Hemoglobin A1c |
0 |
0.17 |
| Clinical Research |
0 |
0.12 |
| Diet |
0 |
0.12 |
| DPP-4 Inhibitors |
0 |
0.12 |
| Exercise |
0 |
0.12 |
| Hemoglobin |
0 |
0.12 |
| Hospital |
0 |
0.12 |
| Insurance |
0 |
0.12 |
| Metabolism |
0 |
0.12 |
| Revenue and Practice Management |
0 |
0.12 |
| SGLT2 Inhibitor |
0 |
0.12 |
| Healthcare and Medical Technology |
0 |
0.05 |